DMAC News and Press, DiaMedica Therapeutics Inc. From 07/21/25

2025-07-21 08:27:48 ET More on DiaMedica Therapeutics DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes Seeking Alpha’s Quant Rating on DiaMedica Therapeuti...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by c...

2025-07-17 11:14:46 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 inte...

Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central Time DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for Combined Cohorts 6-9 DM199 Did Not Cross the Placental Barri...

2025-06-24 08:47:46 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after th...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jeff...

Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM Central DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virt...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in ...

2025-05-14 11:06:10 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript DiaMed...